Literature DB >> 23881576

Renal denervation for arrhythmias: hope or hype?

Jonathan S Steinberg1, Evgeny Pokushalov, Suneet Mittal.   

Abstract

Renal artery denervation (RDN) has been introduced as an ablation procedure that can effectively treat drug-resistant forms of hypertension. The ablative lesions reduce the afferent and efferent sympathetic nerve traffic to and from the kidneys, thus improving blood pressure control. Because of better control of blood pressure, and because the procedure reduces central sympathetic output to sensitive structures within the cardiovascular system, it has been hypothesized that RDN may be a valuable antiarrhythmic intervention. Preliminary results using RDN for atrial fibrillation control are promising. This review focuses on the mechanisms by which RDN may function as an antiarrhythmic treatment and early clinical results.

Entities:  

Mesh:

Year:  2013        PMID: 23881576     DOI: 10.1007/s11886-013-0392-0

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  29 in total

Review 1.  Functional role of renal afferents.

Authors:  A Stella; A Zanchetti
Journal:  Physiol Rev       Date:  1991-07       Impact factor: 37.312

2.  Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation.

Authors:  Eugene Patterson; Sunny S Po; Benjamin J Scherlag; Ralph Lazzara
Journal:  Heart Rhythm       Date:  2005-06       Impact factor: 6.343

3.  Effects of high thoracic epidural anesthesia on atrial electrophysiological characteristics and sympathetic nerve sprouting in a canine model of atrial fibrillation.

Authors:  Shu-sen Yang; Wei Han; Yong Cao; Guo Dong; Guo Zhou; Wei-min Li; Run-tao Gan; Hui-ying Chang; Zheng Wang
Journal:  Basic Res Cardiol       Date:  2011-02-13       Impact factor: 17.165

4.  Adverse consequences of high sympathetic nervous activity in the failing human heart.

Authors:  D M Kaye; J Lefkovits; G L Jennings; P Bergin; A Broughton; M D Esler
Journal:  J Am Coll Cardiol       Date:  1995-11-01       Impact factor: 24.094

5.  Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation.

Authors:  Dominik Linz; Felix Mahfoud; Ulrich Schotten; Christian Ukena; Mathias Hohl; Hans-Ruprecht Neuberger; Klaus Wirth; Michael Böhm
Journal:  Hypertension       Date:  2012-11-12       Impact factor: 10.190

6.  Effect of renal sympathetic denervation on the inducibility of atrial fibrillation during rapid atrial pacing.

Authors:  Qingyan Zhao; Shengbo Yu; Minghui Zou; Zixuan Dai; Xule Wang; Jinping Xiao; Congxin Huang
Journal:  J Interv Card Electrophysiol       Date:  2012-08-07       Impact factor: 1.900

7.  Valsartan for prevention of recurrent atrial fibrillation.

Authors:  Marcello Disertori; Roberto Latini; Simona Barlera; Maria Grazia Franzosi; Lidia Staszewsky; Aldo Pietro Maggioni; Donata Lucci; Giuseppe Di Pasquale; Gianni Tognoni
Journal:  N Engl J Med       Date:  2009-04-16       Impact factor: 91.245

8.  Evidence against reinnervation of cardiac vagal afferents after human orthotopic cardiac transplantation.

Authors:  J A Arrowood; E Goudreau; A J Minisi; A B Davis; P K Mohanty
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

Review 9.  Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives.

Authors:  Guido Grassi
Journal:  Hypertension       Date:  2009-08-31       Impact factor: 10.190

10.  Sympatho-renal axis in chronic disease.

Authors:  Paul A Sobotka; Felix Mahfoud; Markus P Schlaich; Uta C Hoppe; Michael Böhm; Henry Krum
Journal:  Clin Res Cardiol       Date:  2011-06-19       Impact factor: 5.460

View more
  7 in total

Review 1.  Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics.

Authors:  Kalyanam Shivkumar; Olujimi A Ajijola; Inder Anand; J Andrew Armour; Peng-Sheng Chen; Murray Esler; Gaetano M De Ferrari; Michael C Fishbein; Jeffrey J Goldberger; Ronald M Harper; Michael J Joyner; Sahib S Khalsa; Rajesh Kumar; Richard Lane; Aman Mahajan; Sunny Po; Peter J Schwartz; Virend K Somers; Miguel Valderrabano; Marmar Vaseghi; Douglas P Zipes
Journal:  J Physiol       Date:  2016-06-14       Impact factor: 5.182

Review 2.  Catheter-Based Renal Nerve Ablation as a Novel Hypertension Therapy: Lost, and Then Found, in Translation.

Authors:  John W Osborn; Christopher T Banek
Journal:  Hypertension       Date:  2018-01-02       Impact factor: 10.190

Review 3.  Neuromodulation for Ventricular Tachycardia and Atrial Fibrillation: A Clinical Scenario-Based Review.

Authors:  Ching Zhu; Peter Hanna; Pradeep S Rajendran; Kalyanam Shivkumar
Journal:  JACC Clin Electrophysiol       Date:  2019-08-19

4.  Renal sympathetic denervation in addition to pulmonary vein isolation reduces the recurrence rate of atrial fibrillation: an updated meta-analysis of randomized control trials.

Authors:  Jakrin Kewcharoen; Wasawat Vutthikraivit; Pattara Rattanawong; Narut Prasitlumkum; Nazem W Akoum; T Jared Bunch; Leenhapong Navaravong
Journal:  J Interv Card Electrophysiol       Date:  2020-05-12       Impact factor: 1.900

5.  Differential role of afferent and efferent renal nerves in the maintenance of early- and late-phase Dahl S hypertension.

Authors:  Jason D Foss; Gregory D Fink; John W Osborn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-12-09       Impact factor: 3.619

6.  Device-Based Approaches to Modulate the Autonomic Nervous System and Cardiac Electrophysiology.

Authors:  William J Hucker; Jagmeet P Singh; Kimberly Parks; Antonis A Armoundas
Journal:  Arrhythm Electrophysiol Rev       Date:  2014-05-30

Review 7.  Renal sympathetic nervous system and the effects of denervation on renal arteries.

Authors:  Arun Kannan; Raul Ivan Medina; Nagapradeep Nagajothi; Saravanan Balamuthusamy
Journal:  World J Cardiol       Date:  2014-08-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.